According to a new report published by Allied Market Research, titled, "Protein Engineering Market," The protein engineering market was valued at $2.2 billion in 2022, and is estimated to reach $7.7 billion by 2032, growing at a CAGR of 13.2% from 2023 to 2032.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
Key Market Segments
By End User
- Pharmaceutical and Biotechnology Companies
- Academic Research Institutes
- Contract Research Organizations
By Product
- Instruments
- Consumables
- Software
By Technology Type
- Rational or Site Directed Mutagenesis
- Irrational or Random Mutagenesis
By Protein Type
- Monoclonal Antibodies
- Insulin
- Erythropoietin
- Interferon
- Others
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- Agilent Technologies, Inc.
- Promega Corporation
- New England Biolabs, Inc.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Amgen, Inc.
- TAKARA HOLDINGS INC.
- Thermo Fisher Scientific Inc.
- Creative Biolabs Limited
- Jena Bioscience GmbH